Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® (CT-P42, aflibercept), a biosimilar to Eylea® to ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

If you buy something, we may earn an affiliate commission. The best jewelry brands do more than accessorize—they elevate, transform, and complete any outfit. As a jewelry designer, I know ...

Something that does the talking so she can use her words for the boardroom. We’ve looked into high-end purse brands that feel and smell like luxury and not all need to have a major price tag ...

Still, it remains an iconic brand with some of the most cutting edge TVs out there. It pushes the envelope with its QD-OLED technology, whilst offering some of the brightest and boldest QLED TVs.

Teva Pharmaceutical Industries Ltd (NYSE ... A: Richard Francis, CEO, explained that the partnership with Sanofi involves a 50-50 cost share for the duvakitug program. The focus is on capital ...

On Feb. 22, Sanofi’s partner Teva will present more detailed information on its previously announced phase 2 data for duvakitug (TL1A inhibitor) in ulcerative colitis and Crohn’s disease at ...

Teva Pharmaceutical Industries Ltd (NYSE ... explained that the partnership with Sanofi involves a 50-50 cost share for the duvakitug program. The focus is on capital allocation to ensure ...